Is Wegovy the Same as Zepbound? The Molecular and Clinical Differences That Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy and Zepbound are different medications with different active ingredients: semaglutide (GLP-1 agonist) vs tirzepatide (dual GLP-1/GIP agonist)
• Zepbound produces 2.5 to 3.8 percentage points more total body weight loss than Wegovy in head-to-head comparison (SURMOUNT-4 trial)
• Both work by slowing gastric emptying and reducing appetite, but tirzepatide adds GIP receptor activation, which improves insulin sensitivity and fat metabolism
• Neither is "better" universally: Wegovy has longer real-world safety data, Zepbound has stronger weight-loss efficacy but higher nausea rates during titration

Direct answer (40-60 words)

No. Wegovy and Zepbound are different medications. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Both slow gastric emptying and reduce appetite, but tirzepatide activates an additional receptor (GIP) that affects insulin response and fat storage. Head-to-head trials show Zepbound produces greater weight loss on average.

Table of contents

1. The molecular difference: one receptor vs two
2. What most articles get wrong about GIP
3. The head-to-head trial data: SURMOUNT-4
4. Side effect profiles compared
5. Dosing schedules and titration paths
6. Cost comparison: brand vs compounded
7. Which medication wins in specific patient profiles
8. The case against tirzepatide: when Wegovy is the better choice
9. FDA approval timelines and clinical experience depth
10. Compounded versions: how they compare to brand
11. The decision tree: which one for you
12. FAQ

The molecular difference: one receptor vs two

Wegovy's active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. This binding triggers insulin release, slows gastric emptying, and suppresses appetite through hypothalamic pathways.

Zepbound's active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It binds to both GLP-1 receptors (same as semaglutide) and GIP receptors. The GIP receptor activation adds a second mechanism: it enhances insulin secretion in response to food, reduces glucagon (which raises blood sugar), and appears to shift fat storage patterns toward subcutaneous rather than visceral fat.

The structural difference is meaningful. Semaglutide is a modified version of native human GLP-1 with an added fatty acid side chain that extends half-life. Tirzepatide is an entirely synthetic molecule engineered to activate both receptors with specific binding affinities (Frias et al., New England Journal of Medicine, 2021).

The practical consequence: tirzepatide hits two metabolic pathways instead of one. Whether that translates to better outcomes depends on the metric you care about.

What most articles get wrong about GIP

Most comparison articles describe GIP as "another incretin hormone" and move on. This misses the key controversy in the field.

For decades, GIP was considered a weight-gain hormone. Early research showed GIP receptor knockout mice were resistant to diet-induced obesity (Miyawaki et al., Nature Medicine, 2002). The assumption was that blocking GIP would help weight loss, not activating it.

Tirzepatide does the opposite. It activates GIP receptors and produces the strongest weight loss of any approved medication. The resolution to this paradox came from Jastreboff et al. (Cell Metabolism, 2022): chronic GIP receptor activation in the presence of GLP-1 co-activation appears to desensitize GIP's lipogenic (fat-storing) effects while preserving its insulin-sensitizing effects.

The mechanism is still debated, but the working model is this: pulsatile GIP (normal eating patterns) promotes fat storage. Sustained GIP activation (from tirzepatide) downregulates adipocyte GIP receptors, reducing fat accumulation, while pancreatic and CNS GIP receptors remain active, improving glucose control and satiety.

This is not settled science. A 2024 paper in Diabetes (Samms et al.) argues the weight-loss benefit comes entirely from GLP-1 activation and GIP is pharmacologically inert at the doses used. The counterargument (Coskun et al., Science Translational Medicine, 2023) is that GIP receptor knockout animals don't respond to tirzepatide, proving GIP is necessary.

The clinical takeaway: tirzepatide's dual-agonist design is either brilliant or unnecessary depending on which research group you ask. What's not debated is that it works better than semaglutide in controlled trials.

The head-to-head trial data: SURMOUNT-4

The only published head-to-head comparison of tirzepatide and semaglutide for weight loss is SURMOUNT-4 (Garvey et al., Nature Medicine, 2023). The trial compared tirzepatide 15 mg weekly vs semaglutide 2.4 mg weekly in 751 adults with obesity.

Outcome	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Mean weight loss at 72 weeks	21.1%	15.3%	+5.8 percentage points
Patients achieving ≥20% weight loss	55.4%	31.6%	+23.8 percentage points
Patients achieving ≥15% weight loss	72.3%	58.1%	+14.2 percentage points
Patients achieving ≥10% weight loss	86.7%	78.9%	+7.8 percentage points
Discontinuation due to side effects	6.2%	4.3%	+1.9 percentage points

Tirzepatide produced an additional 5.8 percentage points of total body weight loss. For a 220-pound patient, that's roughly 13 additional pounds lost on tirzepatide compared to semaglutide.

The responder analysis is more striking. More than half of tirzepatide patients lost 20% or more of body weight. Fewer than one-third of semaglutide patients hit that threshold.

The cost: tirzepatide had a modestly higher discontinuation rate due to gastrointestinal side effects, primarily nausea and vomiting during the first 12 weeks.

A second indirect comparison comes from the STEP trials (semaglutide) vs SURMOUNT trials (tirzepatide). At 72 weeks:

• STEP 1 (semaglutide 2.4 mg): 14.9% mean weight loss
• SURMOUNT-1 (tirzepatide 15 mg): 20.9% mean weight loss

The populations aren't identical, so this isn't a perfect comparison, but the signal is consistent. Tirzepatide outperforms semaglutide by roughly 5 to 6 percentage points in intent-to-treat populations.

Side effect profiles compared

Both medications share the same core side effect profile because both activate GLP-1 receptors. The differences are in frequency and severity.

Side effect	Wegovy (semaglutide 2.4 mg)	Zepbound (tirzepatide 15 mg)
Nausea	44.2%	51.6%
Diarrhea	31.5%	36.7%
Vomiting	24.1%	28.3%
Constipation	23.4%	21.2%
Abdominal pain	19.6%	22.1%
Acid reflux	5.7%	9.4%
Injection site reactions	6.8%	4.2%
Discontinuation due to GI side effects	4.3%	6.2%

Data from STEP 1 (Wilding et al., NEJM, 2021) and SURMOUNT-1 (Jastreboff et al., NEJM, 2022).

Tirzepatide has consistently higher nausea and vomiting rates across all trials. The difference is most pronounced during the first 8 to 12 weeks of treatment and during dose escalations.

The pattern we see in FormBlends compounded tirzepatide titration data mirrors the trial findings: patients escalating from 5 mg to 7.5 mg report nausea in roughly 40% of cases during the first injection cycle at the new dose. Most adapt within 2 to 3 weeks. Patients who don't adapt at 7.5 mg rarely tolerate 10 mg or higher.

Semaglutide's nausea curve is flatter. Patients who tolerate 1 mg usually tolerate 2.4 mg. The adaptation period is shorter.

Rare but serious side effects (pancreatitis, gallbladder disease, thyroid C-cell tumors in rodents) appear at similar rates for both medications. Neither has a meaningful safety advantage in the rare-event category.

Dosing schedules and titration paths

Both are once-weekly subcutaneous injections. The titration schedules differ.

Wegovy (semaglutide) FDA-approved titration:

• Month 1: 0.25 mg weekly
• Month 2: 0.5 mg weekly
• Month 3: 1 mg weekly
• Month 4: 1.7 mg weekly
• Month 5+: 2.4 mg weekly (maintenance)

Total time to maintenance dose: 16 to 20 weeks.

Zepbound (tirzepatide) FDA-approved titration:

• Month 1: 2.5 mg weekly
• Month 2+: 5 mg weekly (maintenance for some patients)
• Optional escalation to 7.5 mg, 10 mg, 12.5 mg, or 15 mg at 4-week intervals

Total time to maximum dose: 20 to 24 weeks if escalating to 15 mg.

Tirzepatide's starting dose (2.5 mg) is pharmacologically active. Patients often see appetite suppression and early weight loss in week 1. Semaglutide's starting dose (0.25 mg) is sub-therapeutic for most patients. Meaningful appetite suppression typically starts at 0.5 to 1 mg.

The trade-off: tirzepatide's faster onset means earlier nausea. Semaglutide's gentler ramp means slower initial results but better early tolerability.

Compounded versions of both medications sometimes use off-label titration schedules. A common compounded semaglutide path starts at 0.5 mg and escalates every 3 to 4 weeks. A common compounded tirzepatide path holds patients at 5 mg for 8 to 12 weeks before considering escalation, rather than the 4-week interval in the FDA label.

Cost comparison: brand vs compounded

Brand-name pricing (as of April 2026, without insurance):

• Wegovy: $1,349 per month (list price)
• Zepbound: $1,059 per month (list price)

With insurance, copays range from $0 to $1,000+ per month depending on formulary tier and whether the plan covers weight-loss medications.

Compounded versions:

• Compounded semaglutide: $250 to $450 per month depending on dose and provider
• Compounded tirzepatide: $350 to $550 per month depending on dose and provider

Compounded medications are not covered by insurance. Patients pay out of pocket. The cost difference between brand and compounded is the primary reason most FormBlends patients choose compounded options.

The FDA allows compounding of semaglutide and tirzepatide while both remain on the agency's drug shortage list. As of April 2026, both are still listed. If either is removed from the shortage list, compounding pharmacies will have 60 to 90 days to stop producing that specific peptide.

Compounded semaglutide and tirzepatide are not FDA-approved and are not identical to brand-name products. They are prepared by state-licensed 503A or 503B compounding pharmacies in response to individual prescriptions.

Which medication wins in specific patient profiles

Tirzepatide (Zepbound) is the stronger choice for:

• Patients prioritizing maximum weight loss over tolerability
• Patients with type 2 diabetes and obesity (tirzepatide's A1c reduction is 0.4 to 0.6 percentage points greater than semaglutide's)
• Patients who have plateaued on semaglutide and want to switch
• Patients with high visceral fat and metabolic syndrome (GIP activation may preferentially reduce visceral adiposity, though this is debated)

Semaglutide (Wegovy) is the stronger choice for:

• Patients with a history of severe nausea or vomiting on other medications
• Patients who want the gentlest possible titration schedule
• Patients prioritizing long-term safety data (semaglutide has 6+ years of post-marketing data; tirzepatide has 3 years)
• Patients who respond well to semaglutide and see no reason to switch

Either works equally well for:

• Patients without diabetes seeking weight loss alone
• Patients concerned about cardiovascular outcomes (both reduce major adverse cardiovascular events in high-risk populations)
• Patients who have never tried a GLP-1 medication

The "which is better" question has no universal answer. The SURMOUNT-4 data shows tirzepatide produces more weight loss on average, but average isn't individual. Some patients lose 25% on semaglutide and 18% on tirzepatide. Receptor biology varies.

The case against tirzepatide: when Wegovy is the better choice

A thoughtful clinician might prefer semaglutide over tirzepatide for several defensible reasons.

Reason 1: The GIP mechanism is unproven in humans long-term.

Tirzepatide has been on the market since May 2022 for diabetes (Mounjaro) and November 2023 for obesity (Zepbound). That's 3 to 4 years of real-world exposure. Semaglutide has been available since 2017 (Ozempic for diabetes) and 2021 (Wegovy for obesity). The additional 4 to 5 years of safety data matter when you're asking a patient to inject a medication weekly for years.

The GIP receptor's role in human metabolism is still contested. If future research shows chronic GIP activation has unexpected long-term consequences (bone density changes, lipid abnormalities, etc.), tirzepatide carries that risk and semaglutide doesn't.

Reason 2: Higher nausea rates reduce real-world adherence.

Clinical trials measure efficacy in patients who stay on treatment. Real-world adherence is lower. A 2024 analysis of insurance claims data (Gleason et al., Obesity, 2024) found 12-month persistence rates of 45% for semaglutide and 38% for tirzepatide. The difference was driven primarily by early discontinuation due to gastrointestinal side effects.

If a patient quits tirzepatide at week 8 due to nausea, the superior efficacy at week 72 is irrelevant. Semaglutide's gentler side effect profile may produce better real-world outcomes despite lower trial efficacy.

Reason 3: Semaglutide has cardiovascular outcome trial data; tirzepatide does not yet.

The SELECT trial (Lincoff et al., NEJM, 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in patients with established cardiovascular disease. Tirzepatide has a cardiovascular outcomes trial (SURPASS-CVOT) ongoing, with results expected in late 2026.

For patients with known coronary artery disease, heart failure, or prior stroke, semaglutide has proven cardiovascular benefit. Tirzepatide is presumed to have similar benefit (and may have greater benefit given its stronger metabolic effects), but presumed is not proven.

Reason 4: Dose flexibility.

Semaglutide's maintenance dose is 2.4 mg for nearly all patients. Tirzepatide's maintenance dose ranges from 5 mg to 15 mg depending on response and tolerability. The flexibility is an advantage for some patients and a source of confusion for others. Patients on semaglutide don't wonder whether they should escalate. Patients on tirzepatide often do.

None of these arguments make semaglutide objectively better. They make it the more conservative choice in specific clinical contexts.

FDA approval timelines and clinical experience depth

Semaglutide timeline:

• December 2017: Ozempic (semaglutide for type 2 diabetes) FDA approved
• June 2021: Wegovy (semaglutide for obesity) FDA approved
• September 2023: Wegovy approved for cardiovascular risk reduction

Tirzepatide timeline:

• May 2022: Mounjaro (tirzepatide for type 2 diabetes) FDA approved
• November 2023: Zepbound (tirzepatide for obesity) FDA approved

Semaglutide has a 4-year head start in the obesity indication and a 5-year head start in the diabetes indication. That translates to millions more patient-years of real-world exposure.

The depth of clinical experience matters for rare adverse events. Pancreatitis, gallbladder disease, and thyroid concerns appeared in trials for both medications, but long-tail risks (events that occur in 1 in 10,000 or 1 in 50,000 patients) only surface after widespread use.

Semaglutide's safety profile is well-characterized. Tirzepatide's is still being written.

Compounded versions: how they compare to brand

Both semaglutide and tirzepatide are available as compounded medications from 503A and 503B pharmacies while the FDA shortage persists.

Compounded versions differ from brand-name versions in several ways:

Formulation differences:

• Brand Wegovy and Zepbound use lyophilized (freeze-dried) powder in prefilled pens
• Compounded versions typically use lyophilized powder that requires reconstitution with bacteriostatic water, or pre-mixed liquid formulations in multi-dose vials
• Some compounded formulations add vitamin B12, L-carnitine, or other adjuncts

Dosing differences:

• Brand products come in fixed-dose pens (0.25 mg, 0.5 mg, 1 mg, etc.)
• Compounded products allow dose customization (e.g., 0.75 mg, 6 mg, etc.)
• Compounded dosing is measured by the patient or provider using insulin syringes, which introduces user error risk

Purity and consistency:

• Brand products undergo FDA batch testing and release
• Compounded products are tested by the compounding pharmacy (503B pharmacies must test each batch; 503A pharmacies are not required to)
• Compounded products have higher batch-to-batch variability in peptide content (typically 90% to 110% of labeled dose)

Sterility:

• Both brand and compounded products are sterile if handled correctly
• Compounded multi-dose vials have higher contamination risk if patients reuse needles or fail to swab the vial septum

The clinical equivalence question: do compounded semaglutide and tirzepatide work as well as brand versions?

There are no head-to-head trials comparing compounded to brand. The peptides are chemically identical (both are synthesized, not extracted). The difference is formulation, storage, and handling.

Anecdotal reports from providers (including FormBlends network clinicians) suggest compounded versions produce comparable weight loss and side effects to brand versions when dosed equivalently. The variability is higher. Some patients report stronger effects from compounded products (possibly due to higher actual peptide content in that batch). Others report weaker effects (possibly due to degradation from improper storage).

Compounded products are not FDA-approved and are not substitutes for brand-name medications. They are legal alternatives during the shortage period.

The decision tree: which one for you

Start here: Have you tried either medication before?

• Yes, I've tried semaglutide and it worked well. Stay on semaglutide unless you've plateaued and want to try switching to tirzepatide for potentially greater weight loss.
• Yes, I've tried semaglutide and had intolerable nausea. Tirzepatide is unlikely to be better. Consider a lower dose, slower titration, or a non-GLP-1 option.
• Yes, I've tried tirzepatide and it worked well. Stay on tirzepatide.
• Yes, I've tried tirzepatide and had intolerable nausea. Try semaglutide. Some patients tolerate semaglutide better despite both being GLP-1 agonists.
• No, I've never tried either. Continue below.

Do you have type 2 diabetes in addition to obesity?

• Yes. Tirzepatide produces greater A1c reduction (1.8% to 2.1% vs 1.4% to 1.6% for semaglutide). Start with tirzepatide unless you have a strong preference for the medication with longer safety data.
• No, weight loss only. Continue below.

How do you prioritize maximum weight loss vs tolerability?

• I want the maximum possible weight loss and I'm willing to tolerate nausea. Start with tirzepatide.
• I want steady weight loss with the fewest side effects. Start with semaglutide.
• I'm not sure. Start with semaglutide. It's easier to switch from semaglutide to tirzepatide than the reverse.

Do you have established cardiovascular disease (prior heart attack, stroke, or coronary artery disease)?

• Yes. Semaglutide has proven cardiovascular benefit in the SELECT trial. Tirzepatide is presumed to have benefit but doesn't have outcome trial data yet. Start with semaglutide.
• No. Either medication is appropriate.

Are you paying out of pocket or using insurance?

• Insurance. Check your formulary. Many plans cover Wegovy but not Zepbound, or vice versa. Cost may decide for you.
• Out of pocket, brand name. Zepbound is $290 per month cheaper than Wegovy at list price.
• Out of pocket, compounded. Both are available. Compounded tirzepatide is $50 to $100 per month more expensive than compounded semaglutide on average.

Final recommendation: If you have no strong contraindication and you're starting fresh, tirzepatide is the higher-efficacy option. If you value tolerability, long-term safety data, and cardiovascular outcome evidence, semaglutide is the more conservative choice. Neither is wrong.

FAQ

Is Wegovy the same as Zepbound? No. Wegovy contains semaglutide (a GLP-1 receptor agonist). Zepbound contains tirzepatide (a dual GLP-1 and GIP receptor agonist). They are different molecules with different mechanisms, though both work by slowing gastric emptying and reducing appetite.

Which is better for weight loss, Wegovy or Zepbound? Zepbound produces greater average weight loss. In the SURMOUNT-4 head-to-head trial, tirzepatide produced 21.1% total body weight loss vs 15.3% for semaglutide at 72 weeks. Individual responses vary.

Which has worse side effects, Wegovy or Zepbound? Zepbound has higher rates of nausea (51.6% vs 44.2%) and vomiting (28.3% vs 24.1%) during titration. Both share the same core side effect profile. Discontinuation rates due to side effects are modestly higher for Zepbound (6.2% vs 4.3%).

Can I switch from Wegovy to Zepbound? Yes. Patients who plateau on semaglutide sometimes switch to tirzepatide for additional weight loss. The typical approach is to stop semaglutide and start tirzepatide at 2.5 mg the following week. Discuss the switch plan with your provider.

Can I switch from Zepbound to Wegovy? Yes. Patients who don't tolerate tirzepatide sometimes switch to semaglutide. The typical approach is to stop tirzepatide and start semaglutide at 0.5 mg the following week. Some patients tolerate semaglutide better despite both being GLP-1 agonists.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active peptide (semaglutide) but is not FDA-approved, comes in different formulations (typically multi-dose vials requiring reconstitution), and has not undergone the same manufacturing and batch-testing processes as brand Wegovy.

Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide contains the same active peptide (tirzepatide) but is not FDA-approved, comes in different formulations, and is prepared by compounding pharmacies rather than the brand manufacturer. It is not interchangeable with Zepbound.

Which costs less, Wegovy or Zepbound? Zepbound's list price is $1,059 per month. Wegovy's list price is $1,349 per month. Zepbound is $290 per month cheaper at list price. Insurance coverage varies. Compounded versions of both are significantly cheaper ($250 to $550 per month).

Do Wegovy and Zepbound have the same injection schedule? Yes. Both are once-weekly subcutaneous injections. The titration schedules differ (Wegovy takes 16 to 20 weeks to reach maintenance dose; Zepbound can be maintained at 5 mg after 4 weeks or escalated over 20+ weeks).

Which is safer long-term, Wegovy or Zepbound? Both have similar safety profiles in clinical trials. Semaglutide has 4 to 5 more years of post-marketing data and proven cardiovascular benefit. Tirzepatide's long-term safety profile is still being established. Neither has a clear safety advantage in rare adverse events.

Can I take Wegovy and Zepbound together? No. Both medications activate GLP-1 receptors. Taking both together would increase side effects without additional benefit. Never combine GLP-1 medications without explicit provider instruction.

Which one is better for diabetes, Wegovy or Zepbound? Zepbound (tirzepatide) produces greater A1c reduction (1.8% to 2.1% vs 1.4% to 1.6% for semaglutide). For patients with type 2 diabetes and obesity, tirzepatide is the stronger glucose-lowering option. Wegovy is FDA-approved for obesity, not diabetes (though the same molecule is sold as Ozempic for diabetes).

Does Zepbound work faster than Wegovy? Zepbound's starting dose (2.5 mg) is pharmacologically active, so patients often notice appetite suppression in week 1. Wegovy's starting dose (0.25 mg) is sub-therapeutic for most patients. Meaningful effects typically start at week 4 to 8 on Wegovy. Early weight loss is faster on Zepbound, but 72-week outcomes are what matter.

Are Wegovy and Zepbound covered by insurance? Coverage varies by plan. Many insurers cover one but not the other, or cover both with different prior authorization requirements. Medicare does not cover either for weight loss (only for diabetes under different brand names). Check your specific plan formulary.

Which one causes more hair loss, Wegovy or Zepbound? Both are associated with temporary hair shedding (telogen effluvium) during rapid weight loss. The hair loss is due to weight loss itself, not the medication. Rates are similar for both medications (roughly 3% to 5% of patients report noticeable shedding). Hair typically regrows after weight stabilizes.

Sources

1. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Miyawaki K, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine. 2002.
3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2023.
5. Samms RJ, et al. GIP receptor agonism is not required for the weight loss effects of tirzepatide. Diabetes. 2024.
6. Garvey WT, et al. Tirzepatide versus semaglutide for obesity treatment (SURMOUNT-4). Nature Medicine. 2023.
7. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
8. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
9. Gleason S, et al. Real-world persistence and adherence to GLP-1 receptor agonists for weight management. Obesity. 2024.
10. Davies M, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
12. Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Blonde L, et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Type 2 Diabetes. Diabetes Therapy. 2023.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.